+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tedisamil Attenuates Ventricular Fibrillation in a Conscious Canine Model of Sudden Cardiac Death



Tedisamil Attenuates Ventricular Fibrillation in a Conscious Canine Model of Sudden Cardiac Death



Journal of Cardiovascular Pharmacology and Therapeutics 1(4): 313-324



BACKGROUND: The electrophysiologic and antifibrillatory properties of tedisamil (KC-8857;3,7-di-(cyclopropylmethyl)-9,9-tetramethylene-3,7-diazabicyclo[3.3.1]-nonane dihydrochloride) were studied in a conscious canine model of sudden cardiac death. METHODS AND RESULTS: Three to five days after surgically induced myocardial infarction (2-hour occlusion of the left anterior descending coronary artery), animals were subjected to programmed electrical stimulation to identify those at risk for ischemia-induced ventricular fibrillation. Sixty minutes after tedisamil (10 mg/kg, administered orally) PES was repeated. Tedisamil increased the ventricular effective refractory period from 106 +/- 6 to 134 +/- 7 ms (P <.05) compared to placebo treatment, which did not alter the ERP (123 +/- 6 to 116 +/- 5 ms). Tedisamil prolonged the QTc interval, from a predrug value of 308 +/- 14 to 327 +/- 14 ms, postdrug. The extent of the surgically induced anterior wall myocardial infarct did not differ between groups, tedisamil, 29 +/- 2%, and placebo, 28 +/- 2% of the left ventricle. CONCLUSIONS: Tedisamil conferred protection against ischemia induced ventricular fibrillation; 7 of 10 tedisamil-treated dogs survived, compared to 4 of 14 surviving in the vehicle treated group (P <.05). Although we observed instances of vomiting and/or diarrhea in several dogs after a single oral administration of tedisamil, the data indicate that oral administration of tedisamil provides protection from ischemia-induced ventricular fibrillation in the postinfarcted conscious canine. The mechanism by which tedisamil achieves its antifibrillatory effect may be related to its ability to prolong the ERP of the ventricular myocardium without altering ventricular conduction velocity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047535752

Download citation: RISBibTeXText

PMID: 10684432

DOI: 10.1177/107424849600100407


Related references

Tedisamil protects against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 10(3): A33, 1996

5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death. European Journal Of Pharmacology. 306(1-3): 99-106, 1996

Ventricular fibrillation in a conscious canine model of sudden cardiac death Effects of MS-551, a multiple dose regimen. FASEB Journal 8(4-5): A78, 1994

The KATP channel antagonist 5-hydroxydecanoate fails to protect against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 9(3): A605, 1995

Prostacyclin on ventricular fibrillation in a conscious canine model of sudden coronary death. Naunyn-Schmiedeberg's Archives of Pharmacology 321(SUPPL): R54, 1982

Effect of flecainide acetate on ventricular tachycardia induction and ventricular fibrillation prevention in a conscious canine model of sudden death. Journal of the American College of Cardiology 7(2 SUPPL A): 84A, 1986

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-125, 1981

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Journal 105(5): 711-717, 1983

Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. American Heart Journal 109(5 Pt 1): 949-958, 1985

Prevention of ventricular fibrillation by dextro sotalol in a conscious canine model of sudden coronary death. American Heart Journal 109(5 PART 1): 949-958, 1985

Ventricular fibrillation resulting from ischemia at a distant site in conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-218, 1981

Ventricular fibrillation in a conscious canine model of sudden coronary death prevention by chronic amiodarone therapy. American Heart Association Monograph: I-132, 1982

Failure of Thromboxane Synthetase Inhibition to Protect the Postinfarcted Heart against the Induction of Ventricular Tachycardia and Ventricular Fibrillation in a Conscious Canine Model of Sudden Coronary Death. Pharmacology 37(3): 171-186, 1988

Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death. Pharmacology 37(3): 171-186, 1988

MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. Journal of Cardiovascular Pharmacology 25(2): 314-323, 1995